Executive interview – Abacus Health Products

Published on 9 January 2020
 

In this interview, Edison Analyst Max Jacobs discusses Abacus Health Products with Edison President Rachel Carroll after initiating on the company in the fourth quarter of 2019. Max touches on how Abacus differentiates itself amidst the noise in the CBD space.

Max is a leading analyst and thought leader in the cannabis sector, having written multiple sector reports and moderated Edison’s cannabis conference in Israel in September 2019.

Abacus is engaged in the development and commercialization of over-the-counter (OTC) registered topical medications with active pharmaceutical ingredients and which contain organic and natural ingredients, including a cannabinoid-rich hemp extract containing CBD from the Cannabis sativa L plant. The company’s products are aimed at the rapidly growing markets for topical pain relief and therapeutic skincare, and are based on proprietary patent-pending technologies developed by Abacus. Abacus’s formulations combine advanced science with organic and natural ingredients to provide safe relief. The company currently offers two lines of products: CBD CLINIC marketed to the professional practitioner market, and CBDMEDIC marketed to the consumer market. Abacus’s products are offered across the US and are produced by a contract manufacturer in an FDA-registered and audited manufacturing facility.

Share this with friends and colleagues